mProX™ Human CD33 Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- CD Cell Lines
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
There are currently no Customer reviews or questions for mProX™ Human CD33 Stable Cell Line (S01YF-1023-PY222). Click the button above to contact us or submit your feedback about this product.
Casey Jones (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Peyton Davis (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Published Data
Fig.1 Suppression of the native mouse Human CD33m is inhibited by CD33, which increases phagocytosis in BV-2 cells.
When human CD33m is knocked down, it stops human CD33m from increasing phagocytosis. BV-2 cells expressing human CD33 variants were treated with either mouse CD33 targeting RNAi or control/scrambled RNAi, and flow cytometry was used to measure the percentage of rat neuronal debris that was phagocytosed. N is the number of separate cell culture preparations. Solid lines connect repeats performed with the four variant cell lines on the same day.
Ref: Butler, Claire Ann, Peter Thornton, and Guy Charles Brown. "CD33M inhibits microglial phagocytosis, migration and proliferation, but the Alzheimer's disease-protective variant CD33m stimulates phagocytosis and proliferation, and inhibits adhesion." Journal of Neurochemistry 158.2 (2021): 297-310.
Pubmed: 33720433
DOI: 10.1111/jnc.15349
Research Highlights
E Petty, Nicholas. et al. "Efficient long-term multilineage engraftment of CD33-edited hematopoietic stem/progenitor cells in nonhuman primates." Molecular therapy. Methods & clinical development, 2023.
The current study focuses on identifying immunotherapeutic targets that are shared between neoplastic and normal hematopoietic stem and progenitor cells (HSPCs). This is an important issue as it can lead to unwanted toxicities in non-target cells. The researchers aimed to delete or modify these shared targets in order to protect the normal HSPCs. They used a gene-editing technique to delete the V-set domain of CD33, a commonly targeted immune-dominant domain, in the HSPCs of two rhesus macaques. After successful engraftment and up to 20% long-term gene editing in the HSPCs and blood cell lineages, the researchers concluded that this modification did not affect the functionality or differentiation potential of myeloid cells.
E Petty, Nicholas. et al. "Efficient long-term multilineage engraftment of CD33-edited hematopoietic stem/progenitor cells in nonhuman primates." Molecular therapy. Methods & clinical development, 2023.
Pubmed:
37868209
DOI:
10.1016/j.omtm.2023.101121
Huang, Wei. et al. "Role of Flow Cytometry in the Diagnosis of Chronic Myeloid Leukemia." Zhongguo shi yan xue ye xue za zhi, 2023.
The aim of this study was to examine the immunological phenotype of chronic myeloid leukemia (CML) and to investigate its characteristics and significance. CML is a type of cancer that affects the white blood cells. The researchers analyzed data from patients with CML to better understand the condition. Through their analysis, they were able to identify key characteristics of the immunological phenotype in CML and determine its significance in the disease. This study provides valuable insights into the immunological aspects of CML for further research and treatment strategies.
Huang, Wei. et al. "Role of Flow Cytometry in the Diagnosis of Chronic Myeloid Leukemia." Zhongguo shi yan xue ye xue za zhi, 2023.
Pubmed:
37846680
DOI:
10.19746/j.cnki.issn.1009-2137.2023.05.012
